Recombinant Newcastle disease virus vectors have gained a lot of interest for its oncolytic virus therapy and cancer immune therapeutic properties due to its selective replication to high titers in cancer cells. The aim of this study was to find out the oncolytic effects of mesogenic recombinant NDV strain R2B-GFP on murine mammary tumor cell line 4T1 and murine melanoma cell line B16-F10. The anti-tumor effects of R2B-GFP virus were studied via expression of virus transgene GFP in cancer cells, evaluating its cytotoxicity and cell migration efficacies by MTT and wound healing assays respectively. In addition, the underlying apoptotic mechanism of R2B-GFP virus was estimated by TUNEL assay, colorimetric estimation of Caspase-3, 8 and 9 and the estimation of Bax to Bcl-2 ratio. The results showed a significant decrease in viability of both 4T1 and B16-F10 cells infected with R2B-GFP virus at 0.1 and 1 MOI. R2B-GFP virus could significantly induce apoptosis in the 4T1 and B16-F10 cells as compared to the uninfected control. Further, a flow cytometry analysis on apoptotic cells percentage and mitochondria membrane permeability test was also studied in R2B-GFP virus treated 4T1 and B16-F10 cell lines. The R2B-GFP virus caused an increase in loss of mitochondrial membrane permeability in both 4T1 and B16-F10 cells indicating the involvement of mitochondrial regulated cell death. Thus, the recombinant virus R2B-GFP virus proved to be a valid candidate for oncolytic viral therapy in 4T1 and B16-F10 cells.

重组新城疫病毒载体因其溶瘤病毒治疗和癌症免疫治疗特性而受到广泛关注，因为其选择性复制到癌细胞中的高滴度。本研究的目的是找出介晶重组 NDV 毒株 R2B-GFP 对鼠乳腺肿瘤细胞系 4T1 和鼠黑色素瘤细胞系 B16-F10 的溶瘤作用。R2B-GFP病毒的抗肿瘤作用进行了研究通过病毒转基因GFP在癌细胞中的表达，分别通过MTT和伤口愈合试验评估其细胞毒性和细胞迁移功效。此外，R2B-GFP 病毒的潜在凋亡机制通过 TUNEL 测定、Caspase-3、8 和 9 的比色估计以及 Bax 与 Bcl-2 比率的估计进行了估计。结果显示，以 0.1 和 1 MOI 感染 R2B-GFP 病毒的 4T1 和 B16-F10 细胞的活力均显着降低。与未感染的对照相比，R2B-GFP 病毒可显着诱导 4T1 和 B16-F10 细胞凋亡。此外，还在 R2B-GFP 病毒处理的 4T1 和 B16-F10 细胞系中研究了对凋亡细胞百分比和线粒体膜通透性测试的流式细胞术分析。R2B-GFP 病毒导致 4T1 和 B16-F10 细胞线粒体膜通透性损失增加，表明参与了线粒体调节的细胞死亡。因此，重组病毒 R2B-GFP 病毒被证明是 4T1 和 B16-F10 细胞溶瘤病毒治疗的有效候选者。